Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer

Lung Cancer

Volumn 74, Issue 1, 2011, Pages 98-102

  Togashi, Yosuke ^a   Masago, Katsuhiro ^a   Fujita, Shiro ^b   Hatachi, Yukimasa ^a   Fukuhara, Akiko ^a   Nagai, Hiroki ^a   Sakamori, Yuichi ^a   Kim, Young Hak ^a   Mio, Tadashi ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Adverse event; Epidermal growth factor gene mutation; Erlotinib; Gefitinib

Indexed keywords

ERLOTINIB; GEFITINIB;

ACNE; ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; JAPANESE; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN DISEASE; STOMATITIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; JAPAN; LIVER FUNCTION TESTS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; POPULATION GROUPS; QUINAZOLINES; RETROSPECTIVE STUDIES; SKIN DISEASES; TREATMENT FAILURE;

EID: 80052590374     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.022     Document Type: Article

References (23)

1. Baselga J., Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, 23:2445-2459.
2. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
4. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
5. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
6. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
7. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
8. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
9. Cohen M.H., Johnson J.R., Chen Y.F., Sridhara R., Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005, 10:461-466.
10. Cohen M.H., Williams G.A., Sridhara R., Chen G., Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003, 8:303-306.
11. Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267-3279.
12. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20:4292-4302.
13. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2:706-714.
14. Nagai Y., Miyazawa H., Huqun, Tanaka T., Udagawa K., Kato M., et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65:7276-7282.
15. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64:8919-8923.
16. Mitsudomi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007, 98:1817-1824.
17. Toyooka S., Matsuo K., Shigematsu H., Kosaka T., Tokumo M., Yatabe Y., et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 2007, 13:5763-5768.
18. Lind J.S., Posrmus P.E., Heideman D.A., Thunnissen E.B., Bekers O., Smit E.F. Dramatic response to low dose erlotinib of epidermal growth factor mutation positice recurrent non-small lung cancer after severe cutaneous toxicity. J Thorac Oncol 2009, 4:1585-1586.
19. Fukui T., Otani S., Hataishi R., Jiang S.X., Nishii Y., Igawa S., et al. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol 2010, 65:803-806.
20. Takeda M., Okamoto I., Makimura C., Fukuoka M., Nakagawa K. Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. J Thorac Oncol 2010, 5:1103-1104.
21. Chang S.C., Chang C.Y., Chen C.Y., Yu C.J. Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. J Thorac Oncol 2010, 5:1105-1106.
22. Takeda M., Okamoto I., Fukuoka M., Nakagawa K. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. J Clin Oncol 2010, 28:e273-274.
23. Yeo W.L., Riely G.J., Yeap B.Y., Lau M.W., Warner J.L., Bodio K., et al. Erlotinib at a dose of 25mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 2010, 5:1048-1053.